How Research Peptides Are Made

A peptide vial arrives as a few milligrams of white powder, and the gap between that and a stated purity figure on a certificate is where most of the useful information lives. Knowing how the powder was made explains why purity varies between compounds, why longer sequences cost more, and why the number on the label is not quite the number of milligrams of peptide in the vial.

Solid Phase Synthesis Is the Standard Method

Almost every research peptide under roughly fifty amino acids is built by solid phase peptide synthesis, a method developed by Bruce Merrifield in the 1960s that has not been fundamentally improved on since.

The principle is that the growing chain stays anchored to an insoluble resin bead while reagents wash over it. Because the product is attached to a solid and everything else is in solution, purification between steps is just rinsing. That is the insight that made synthetic peptides practical.

The chain is built one residue at a time, from the C-terminus backwards, and each residue requires a two-step cycle.

• Deprotection. The protecting group on the terminal amine of the anchored chain is removed, exposing a reactive site. In Fmoc chemistry, the dominant approach, this is done with a mild base.
• Coupling. The next amino acid, itself protected on every reactive group except the one that should react, is activated and joined to the exposed terminus.

Rinse, repeat. A twenty-residue peptide is forty of these steps.

Why Length Drives Everything

Each coupling step is efficient but not perfect. If a single cycle runs at 99.5 percent efficiency, which is a respectable figure, the compounded result over forty steps is roughly 82 percent of chains correctly assembled.

Drop the per-step efficiency to 99 percent and the same forty steps yield about 67 percent. The arithmetic is unforgiving, and it compounds against length.

This is why short sequences are cheap and consistently pure, why long ones are expensive, and why the failure products are so troublesome. The chains that went wrong are deletion sequences, missing a single residue, and they are chemically very similar to the correct product. Separating them is the hard part, not making them.

It is also why peptides beyond about fifty residues are generally produced by recombinant expression in bacterial or yeast systems instead. Growth hormone, at 191 residues, is a recombinant product rather than a synthetic one, which is why Ziotropin HGH belongs to a different manufacturing category than the short synthetic sequences in the peptides catalogue.

Cleavage and Purification

Once the sequence is complete, the chain is cleaved from the resin and all the side-chain protecting groups are removed, typically with trifluoroacetic acid. What comes out is crude peptide: the target sequence mixed with deletion sequences, truncated chains, and residual reagents.

Purification is almost always reverse-phase HPLC. The crude mixture is pushed through a column that separates by hydrophobicity, and fractions are collected. The fraction containing the target is identified, pooled and taken forward.

This step is where purity is actually determined. A 99 percent peptide and a 95 percent peptide may have come off the same synthesiser. The difference is how aggressively the fractions were cut, and cutting aggressively means discarding more product.

Lyophilisation

The purified fraction is a dilute aqueous solution, which is not a stable way to store a peptide. Freeze-drying removes the water by sublimation under vacuum, leaving the characteristic white cake or powder.

Lyophilised peptide is stable for extended periods when kept cold and dry. The fluffy, low-density appearance of the cake is normal and says nothing about quantity, which is why a vial can look nearly empty and still contain its stated mass.

What the Certificate Should Show

Four analyses are standard, and a certificate missing any of them is incomplete.

• HPLC purity. Expressed as the percentage of total peak area attributable to the main peak. This is a relative measure, not an absolute one.
• Mass spectrometry. Confirms the molecular weight matches the intended sequence. Purity without identity is not useful.
• Water content and counter-ion content. Peptides are usually isolated as acetate or trifluoroacetate salts and are hygroscopic.
• Net peptide content. The percentage of the vial’s mass that is actually peptide, as opposed to water and counter-ion.

That last line is the one most often absent and most often misread. A vial labelled 10mg may contain 10mg gross, of which perhaps 80 to 90 percent is peptide once salt and bound water are subtracted. Whether the label refers to gross or net mass is a question the certificate should answer. How to read one properly is set out in How to Read a Peptide COA, and the standard applied across this catalogue is described in Canada’s Peptide Research Standard.

Purity and Identity Are Different Questions

A high purity figure on its own does not establish that the right compound is in the vial, and conflating the two is the most common misreading of a certificate.

HPLC purity says that 99 percent of the material eluting from the column came off as one peak. It does not say what that peak is. A synthesis that produced the wrong sequence cleanly would give an excellent purity figure for a compound that is not the one on the label.

Mass spectrometry answers the identity question by confirming molecular weight. Even that has a limit: two sequences containing the same amino acids in a different order have identical mass. Distinguishing those requires sequencing or fragmentation analysis, which is rarely included at this level of the market.

In practice, purity plus mass confirmation plus a reputable synthesis route is the realistic standard. Purity alone is not, and a certificate showing only a purity percentage is showing you the easier half of the picture.

Why Two Vials of the Same Compound Differ

Synthesis route, purification stringency, counter-ion, residual solvent and lyophilisation conditions all vary between manufacturers. Two vials with the same label and the same stated purity can differ measurably in net peptide content and in solubility behaviour.

This is not a defect in the system, it is a consequence of peptides being manufactured rather than mined. It is also the reason lot-level documentation matters more than brand-level reassurance. The full range is in the shop, and sourcing questions are answered in the FAQ.

All products available through Northern Peptides are sold strictly for research purposes only. Nothing in this article constitutes medical advice, and no compound referenced here is approved by Health Canada for human therapeutic use. Researchers are responsible for ensuring their use of any compound complies with applicable laws and institutional guidelines.